share_log

HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $15

Benzinga ·  Dec 13, 2023 06:28

HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from $16 to $15.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment